Edward Lee Carter: Are All DOACs Truly Interchangeable in Real-World Practice?
Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn:
”Apixaban vs Rivaroxaban — are we starting to see separation?
The COBBRA trial (March 2026) adds another important data point to a question many of us deal with daily:
Are all DOACs truly interchangeable in real-world practice?
COBBRA compared Apixaban vs Rivaroxaban in a contemporary patient population, focusing on both effectiveness and bleeding risk.
Key takeaway (high-level):
Apixaban demonstrated a more favorable bleeding profile, while maintaining comparable effectiveness for thromboembolic prevention.
That signal is not entirely new—but it’s becoming more consistent.
Why this matters in practice:
We often think of DOACs as a class.
But clinically, they behave more like related—but distinct—tools.
What COBBRA reinforces:
- Bleeding risk is not uniform across DOACs
- Patient selection still matters (renal function, age, weight, comorbidities)
- ‘One-size-fits-all anticoagulation’ continues to fall short
Practical considerations:
Apixaban
- Lower observed bleeding rates in multiple datasets
- BID dosing (may improve peak/trough stability)
Rivaroxaban
- Once-daily dosing (adherence advantage for some patients)
- Still a strong, guideline-supported option
The bigger picture:
We’re seeing convergence from:
- RCTs
- Real-world data
- Now additional comparative trials like COBBRA
And the trend is fairly consistent:
- Apixaban often emerges with a bleeding advantage
- Effectiveness remains comparable
For clinicians:
This isn’t about declaring a ‘winner.’
It’s about refining decisions at the bedside.
Matching the right anticoagulant to the right patient
Balancing bleeding risk vs adherence vs comorbidity profile
Bottom line:
DOACs may share a mechanism – but they do not share identical clinical outcomes.”
Stay updated with Hemostasis Today.
-
Mar 26, 2026, 15:50Vicky Kumar: How Best to Manage Patients with Patent Foramen Ovale After a Cryptogenic Stroke
-
Mar 26, 2026, 15:46Faizan Khan: Key Findings on Long Term Stroke Risk After TIA and Minor Stroke
-
Mar 26, 2026, 15:441 in 4 Will Have a Stroke, It is More Common than People Think and It Does Not Discriminate – European Stroke Organisation
-
Mar 26, 2026, 15:39Fabrice Cognasse: Platelets May Play a Much Broader Role in Regulating Inflammation
-
Mar 26, 2026, 15:27Maxime Dely: Anticoagulant Is an Invisible Yet Essential Ally of Therapeutic Apheresis
-
Mar 26, 2026, 15:24Colleen Silk: Fueling Innovation in Rare Bleeding Disorders at THSNA 2026
-
Mar 26, 2026, 15:19Wolfgang Miesbach: A Remarkable Progress With Non-Factor Therapies in Hemophilia Care
-
Mar 26, 2026, 15:19Attilio Cotroneo: Updated Evidence-Based Recommendations for the Management of BTAI
-
Mar 26, 2026, 15:14Rodrigo Assar: Thrombosis Risk Prediction in Pediatric Central Lines